Promoter holding
64.27%
AP
Abbott Pharma Limited - Due diligence report
A 360° intelligence report on Abbott Pharma Limited: trust score, financial health, credit view, compliance, directors, growth and distress …
AP
Abbott Pharma Limited
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Abbott Pharma Limited — 360° Intelligence Report
Generated from MCA filings & public records86/100
Trust Score
Low Risk
Abbott Pharma Limited is assessed as Low Risk with a Trust Score of 86/100. Abbott Pharma Limited is an active public limited indian non-government company incorporated in 2008, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 17 Jul 2026 from the latest processed filings. Abbott Pharma Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
86/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
75/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 75/100 Low Risk
- No open charges - unencumbered balance sheet.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 0 open (-) · 0 satisfied (-).
Compliance Score: 100/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
05
Director Intelligence
Stability score: 85/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| PANKAJ KUMAR JHA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MAN MOHAN SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NEETIKA GOEL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 3 directors on the board.
- No disqualified or deactivated DINs.
- 3 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2018)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2018 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 2 transfer(s)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 65 · Distress 75
Growth signals & trust indicators
Profit expanded 38% year-on-year.
Net margin improved to 1.42.
Operating for 18+ years.
Distress signals & risk flags
Revenue declined year-on-year.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence88/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment81/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance record supports lending.
Investor view74/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events11 May 2025
Last AGM held
Annual general meeting
10 May 2025
Director ceased
NEETIKA GOEL
31 Mar 2025
Latest balance sheet
Filed with ROC
08 Nov 2024
Director appointed
NEETIKA GOEL (Director)
03 May 2024
Director ceased
KUSUM PAL SHARMA
Director ceased
MAN MOHAN SHARMA
08 Apr 2023
Director appointed
MAN MOHAN SHARMA (Director)
12 May 2019
Director ceased
PANKAJ KUMAR JHA
Director ceased
PRATIMA PUJARA
08 Jun 2018
Director appointed
PANKAJ KUMAR JHA (Director)
Director ceased
RASHMI GUPTA
21 May 2018
Director ceased
JASWANT SINGH
03 Aug 2017
Director ceased
ARUN ABBOTT
22 May 2017
Director ceased
ANSHUL KATHURIA
31 Mar 2016
Share transfer (FY 2016)
12000.00000000 shares to Manmohan
10
Key Observations
Auto-generated from the data aboveRevenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
| Company | CIN | Location |
|---|---|---|
| Pentacle Healthcare Private Limited | U74999MH2014PTC258368 | Nerul, Maharashtra, India |
| Pws Surgimed Solutions Private Limited | U74999DL2016PTC289278 | Delhi, Delhi, India |
| Donekar Ayurveda Private Limited | U74999MH2017PTC302740 | Nagpur, Maharashtra, India |
| Sharda Medicoss Private Limited | U85190MH2014PTC254910 | Navi Mumbai, Maharashtra, India |
| Barasat City Life Diagnostic Centre Private Limited | U85110WB2007PTC114005 | Kolkata, West Bengal, India |
| Arin Enterprises Private Limited | U85100GJ2011PTC067168 | Vadodara, Gujarat, India |
| Midas Physio Cure Private Limited | U74999PN2017PTC173347 | Pune, Maharashtra, India |
| Bizsphere Enterprises Private Limited | U51909MH2017PTC294005 | Aurangabad, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Abbott Pharma Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Abbott Pharma Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 75/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 65/100, margin trends, ownership structure and peer set for Abbott Pharma Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 86/100, distress signals and MSME payment-delay disclosures - know whether Abbott Pharma Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Abbott Pharma Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Abbott Pharma Limited an active company?
Abbott Pharma Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).
Is Abbott Pharma Limited financially healthy?
Abbott Pharma Limited has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.
Should I do business with Abbott Pharma Limited?
Its overall Trust Score is 86/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Abbott Pharma Limited?
See the directors and ownership sections above for board and shareholding detail. 3 active director(s) are on record.
Does Abbott Pharma Limited have loans or charges against its assets?
No charges are registered against this company - an unencumbered balance sheet.
Is Abbott Pharma Limited up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).
Is it risky to lend to Abbott Pharma Limited?
Its Credit Risk Score is 75/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
